Another month, another big round of performance for a number of biopharma-focused healthcare hedge funds.
Many of the funds posted strong gains in May, and this helped several of them move back into the black for the year, if only temporarily.
The inherently volatile group is heavily dependent on companies without products receiving good news about hoped-for blockbuster drugs in development.
